<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03519555</url>
  </required_header>
  <id_info>
    <org_study_id>16-5010-16</org_study_id>
    <nct_id>NCT03519555</nct_id>
  </id_info>
  <brief_title>BIOSURE™ RG Knee Safety &amp; Performance Study</brief_title>
  <official_title>Safety and Performance of the BIOSURE™ REGENESORB Interference Screw in Knee Ligament Repair and Reconstruction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Smith &amp; Nephew, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Smith &amp; Nephew, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety and Performance of the BIOSURE™ REGENESORB Interference Screw in Knee Ligament Repair
      and Reconstruction
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This post-market clinical follow-up (PMCF) study will prospectively evaluate the short-term
      (6- and 12-month) safety and performance of the BIOSURE REGENESORB Interference Screw when
      used for any of the following:

      Knee repair:

        -  ACL repair Posterior cruciate ligament (PCL) repair

        -  Extra-capsular repairs

        -  Medial collateral ligament (MCL)

        -  Lateral collateral ligament (LCL)

        -  Posterior oblique ligament (POL)

        -  Patellar realignment and tendon repairs

        -  Vastus medialis obliquus advancement

        -  Iliotibial band tenodesis
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 23, 2018</start_date>
  <completion_date type="Anticipated">December 15, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Graft fixation survival</measure>
    <time_frame>6 months</time_frame>
    <description>Survival rate at 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Graft fixation survival</measure>
    <time_frame>12 months</time_frame>
    <description>Survival rate at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft survival at 6 and 12 months</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>where failure is defined as graft repair failure for any reason</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life - International Knee Documentation Committee Score</measure>
    <time_frame>Pre-Op, 6 months and 12 months</time_frame>
    <description>Patient Reported Outcomes using International Knee Documentation Committee Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life - Tegner Activity Scale</measure>
    <time_frame>Pre-Op, 6 months and 12 months</time_frame>
    <description>Patient Reported Outcomes using Tegner Activity Scale, subject indicates highest level of activity before injury and highest level of activity after injury. Levels on a scale from 0 to 10, with 10 being highest level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life - Lysholm Score</measure>
    <time_frame>Pre-Op, 6 months and 12 months</time_frame>
    <description>Patient Reported Outcomes using Lysholm Score, subject will answer eight questions on how knee pain has affected everyday life. Each question will be answered by placing a checkmark that best describes current condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life - EQ-5D-5L</measure>
    <time_frame>Pre-Op, 6 months and 12 months</time_frame>
    <description>Patient Reported Outcomes using EuroQol Five Dimensions Questionnaire, subject will check box describing health on mobility, self-care, usual daily activities, pain/discomfort, and anxiety/depression. There are five checkbox options for each: no problems, slight, severe, unable to do activity. Subject will indicate from a scale of 1 to 100 (100 best), how good or bad is current health.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>ACL Repair</condition>
  <condition>Posterior Cruciate Ligament (PCL) Repair</condition>
  <condition>Medial Collateral Ligament (MCL)</condition>
  <condition>Lateral Collateral Ligament (LCL)</condition>
  <condition>Posterior Oblique Ligament (POL)</condition>
  <condition>Patellar Realignment and Tendon Repairs</condition>
  <condition>Vastus Medialis Obliquus Advancement</condition>
  <condition>Iliotibial Band Tenodesis</condition>
  <condition>Extra-capsular Repairs</condition>
  <condition>Knee Repair</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All subjects who have received BIOSURE™ REGENESORB Interference Screw in Knee Ligament
        Repair and Reconstruction. This population will be used for safety analysis.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject has provided informed consent for study participation.

          2. Subject is eighteen (18) years of age or older at the time of enrollment in the study.

          3. Subject requires one of the following knee procedures:

               -  Anterior cruciate ligament (ACL) repair

               -  Posterior cruciate ligament (PCL) repair

               -  Extra-capsular repair - Medial collateral ligament (MCL), Lateral collateral
                  ligament (LCL), Posterior oblique ligament (POL)

               -  Patellar realignment and tendon repair Vastus medialis obliquus advancement
                  Iliotibial band tenodesis

          4. Subject is willing and able to comply with study visit schedule and to complete study
             procedures and questionnaires.

        Exclusion Criteria:

          1. Subject has Body Mass Index (BMI) &gt; 40.

          2. Subject has had total knee arthroplasty (TKA) in the study knee.

          3. Subject has conditions that may interfere with graft survival or outcome (e.g. Paget
             disease, vascular insufficiency, muscular atrophy, uncontrolled diabetes, moderate to
             severe renal insufficiency or neuromuscular disease).

          4. Subject has a known allergy to the study device or any of its components.

          5. Subject, in the opinion of the Investigator, has an emotional or neurological
             condition that would pre-empt their willingness to participate in the study, including
             mental illness, mental retardation, drug or alcohol abuse, subject is pregnant, or
             plans to become pregnant during the study.

          6. Subject is entered in another investigational drug, biologic, or device study, or has
             been treated with an investigational product in the past 30 days.

          7. Subject is known to be at risk for loss to follow-up or failure to return for
             scheduled visits.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Eichelkraut</last_name>
    <role>Study Chair</role>
    <affiliation>Vice President</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stacy Leake-Gardner</last_name>
    <phone>901-399-5893</phone>
    <email>Stacy.Leake-Gardner@smith-nephew.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lindsey Munn</last_name>
    <phone>901-399-6124</phone>
    <email>lindsey.munn@smith-nephew.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>OrthoIllinois</name>
      <address>
        <city>Rockford</city>
        <state>Illinois</state>
        <zip>61107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriela Rutiaga</last_name>
      <phone>815-381-7457</phone>
      <email>gabriela.rutiaga@orthoillinois.com</email>
    </contact>
    <investigator>
      <last_name>Geoffrey Van Thiel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OrthoCarolina Research Institute, Inc.</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caleb Michalek</last_name>
      <phone>704-323-3698</phone>
      <email>caleb.michalek@orthocarolina.com</email>
    </contact>
    <investigator>
      <last_name>James Fleischli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kelsey-Seybold Clinic/ Kelsey Research Foundation</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sandra Johnson</last_name>
      <phone>713-442-1224</phone>
      <email>Sandra.Johnson@kelsey-seybold.com</email>
    </contact>
    <investigator>
      <last_name>Anup Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2018</study_first_submitted>
  <study_first_submitted_qc>April 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2018</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

